Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance

Seung In Seo

Hallym University College of Medicine

Byoung Joo

Hallym University College of Medicine

Jin Gu Kang

Hallym University College of Medicine

Hyoung Su Kim

Hallym University College of Medicine

Myoung Kuk Jang

Hallym University College of Medicine

Hak Yang Kim

Hallym University College of Medicine

Woon Geon Shin (✉ sgun9139@gmail.com)

Hallym University College of Medicine <https://orcid.org/0000-0002-9851-5576>

Research article

Keywords: Helicobacter pylori; Clarithromycin; Resistance; Treatment

Posted Date: August 14th, 2019

DOI: <https://doi.org/10.21203/rs.2.12783/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Clinical Medicine on December 25th, 2019. See the published version at <https://doi.org/10.3390/jcm9010054>.

Abstract

Background Clarithromycin resistance in *Helicobacter pylori* (*H. pylori*) is associated with point mutations in the 23S ribosomal RNA (rRNA) gene. A sequencing-based method can detect more point mutations than a polymerase chain reaction (PCR)-based method. We investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant *H. pylori* and compared the *H. pylori* eradication rates based on the identified clinically significant point mutations. **Methods** A total of 431 adult patients with *H. pylori* infection were retrospectively recruited in Kangdong Sacred Heart Hospital in 2017 and 2018. Patients who did not have point mutations related to clarithromycin resistance and/or had clinically insignificant point mutations were treated with PAC (proton pump inhibitor, amoxicillin, clarithromycin) for 7 days, while patients with clinically significant point mutations were treated with PAM (proton pump inhibitor, amoxicillin, metronidazole) for 7 days. *H. pylori* eradication rates were compared between the two groups. **Results** Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant. The clarithromycin resistance rate was 21.3% in the overall group of patients. A2143G was the most clinically significant point mutation (84/431, 19.5%), while T2182C was the most clinically insignificant point mutation (283/431, 65.7%). The *H. pylori* eradication rate in the overall group of patients was 83.7%, and the 7-day PAM-treated clarithromycin-resistance group showed a significantly lower eradication rate than the 7-day PAC-treated nonresistance group [ITT; 55.4% (51/92) vs. 74.3% (252/339), $P=0.001$, PP; 66.2% (51/77) vs. 88.4% (252/285), $P=0.0001$]. **Conclusions** There were significantly lower eradication rates in the patients with clarithromycin-resistant *H. pylori* as identified by the sequencing of point mutations in the 23S rRNA gene when treated with PAM for 7 days. A future study comparing treatment regimens in clarithromycin-resistant *H. pylori*-infected patients may be necessary.

Background

Helicobacter pylori is a gram-negative bacterium that causes gastritis, peptic ulcer, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.¹ *H. pylori* gastritis is considered an infectious disease,^{1,2} and recent meta-analyses have proven that *H. pylori* eradication can significantly improve gastric atrophy.^{3,4} Furthermore, increasing evidence has shown that *H. pylori* eradication might prevent the development of gastric cancer.^{5–7}

Until now, first line therapy for *H. pylori* eradication in Korea involves a regimen of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin for 7–14 days.⁸ However, there has been an increase in the rate of antibiotic resistance in the past two decades, leading to decreased *H. pylori* eradication rates by standard triple therapy.⁹ Clarithromycin resistance associated with a 23S ribosomal RNA (rRNA) point mutation is the most crucial factor in the failure of *H. pylori* eradication. In Korea, the rate of resistance to clarithromycin was reported to be 5.9% before 2000 and has increased up to 21.4% in the period between 2006–2008.^{10,11}

For this reason, the European guideline states that clarithromycin-containing triple therapy without susceptibility testing should be abandoned when clarithromycin resistance rate in the region is higher than 15%.¹ Therefore, tailored *H. pylori* eradication by performing an antibiotic susceptibility test before treatment may be the most reasonable method to reduce the treatment failure; however, the process of bacterial culture is very lengthy and difficult, thus presenting limitations for clinical use.

Recently, there have been increasing evidences of molecular methods for the detection of *H. pylori* resistances to antibiotics such as clarithromycin and quinolones, which have been commonly used until now.^{12–14} Dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) assay detects mutational changes in *H. pylori* obtained from biopsy samples or feces. The method is relatively simple and accurate in finding minimal traces of genotypic resistant strains; however, it can only detect A2143G and A2142G mutations.^{12–14}

Clarithromycin-resistant strains frequently have several point mutations in the 23S rRNA gene, and A-to-G point mutations at positions 2142 and 2143 within the V domain have been demonstrated to be the main mutations; however, little is known regarding the clinical significance of the other point mutations.^{15,16} DNA sequencing can detect more point mutations than DPO-PCR-based methods. There have been a few reports that investigated the clarithromycin resistance of *H. pylori* by sequencing-based detection of 23S rRNA gene point mutations.

The detailed point mutations of clarithromycin-resistant *H. pylori* have yet to be elucidated and effective treatment strategies for areas of high clarithromycin resistance need to be developed. Consequently, this study aimed to investigate point mutations in patients infected with clarithromycin-resistant *H. pylori* and compare the *H. pylori* eradication rates based on the clinically significant point mutations identified by 23S rRNA gene sequencing.

Methods

Patients

A total of 431 patients were recruited in Kangdong Sacred Heart Hospital from January 2017 to September 2018. Subjects who underwent upper endoscopy and were confirmed of *H. pylori* infection by rapid urease test (CLOtest, Pronto Dry New; Medical Instruments Corp, Herford, Germany) ranged from 19–85 years old. The diagnosis of *H. pylori* was confirmed by a typical change in color during the rapid urease test. Mucosal biopsies taken from the antrum and body were used to detect clarithromycin resistance (CAMR)-related point mutations in patients that were positive in the rapid urease test.

Patients were excluded if they had received *H. pylori* eradication therapy within 1 year, antibiotics within 4 weeks, had surgery for gastric cancer, malignant tumors other than gastric cancer, severe systemic disorder such as end-stage renal disease or liver cirrhosis, or pregnancy. This study was approved by the

ethics committee of Kangdong Sacred Heart Hospital, and the protocol conformed with the ethical guidelines of the Declaration of Helsinki (IRB no. 2017–03–005).

Detection of CAMR-related point mutations

H. pylori genomic DNA was isolated from a frozen gastric biopsy specimen that was stored at a temperature of less than -20°C using the MagNA Pure 96 system (Roche Diagnostics, Forrenstrasse, Switzerland) and Viral NA SV Kit (Roche Diagnostics) according to the manufacturer's instructions. PCR was conducted in a final reaction volume of 20 μL containing 4 μg of DNA, 2 μL of primer mixture, and 8 μL of 2 $\times$ Master Mix (Samkwang Medical Laboratories, Seoul, South Korea). After an initial incubation step at 95°C for 10 minutes, 45 amplification cycles were performed in AB SimpliAMP PCR (Applied Biosystems, Foster City, CA), using the following amplification parameters: 95°C for 20 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. The final extension was performed at 72°C for 5 minutes.

Nucleotide sequencing of the amplified DNA was performed using ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA) with BigDye® Terminator V3.1 according to the manufacturer's instructions. All end point PCR reactions, agarose gel electrophoresis, and sequencing work were performed by Samkwang Medical Laboratories (SML, Seoul, Korea). This method can identify mutations in the nucleotide sequence of domain V in the 23S rRNA gene of *H. pylori* by amplifying the first 300 bp of the gene in seven *H. pylori* strains using PCR primers 23S F (5'- CGT AAC TAT AAC GGT CCT AAG –3', corresponding to *H. pylori* 23S rRNA gene positions 2007–2027) and 23S R (5'-TTA GCT AAC AGA AAC ATC AAG - 3', positions 2281–2301) to detect the mutations at positions 2115, 2141, 2142, 2143, 2144, 2147, 2182, 2190, 2195, and 2223.

Analysis of CAMR-related point mutations

We analyzed the distribution of 23S rRNA point mutations associated with clarithromycin resistance detected by sequencing. From a previous study, a PCR-based method mainly detected the point mutations A2143G and A2142G. In Korea, there have been little information about other point mutations; therefore, we regarded A-to-G or A-to-C point mutations at positions 2142 and 2143 as clinically significant point mutations, while other mutations were regarded as clinically insignificant point mutations.

Study design and treatment regimen

The flow diagram of this study is shown in Figure 1. Eradication of *H. pylori* was tailored to the detected CAMR-related point mutations. A2143C, A2143G, A2142G, and A2142C were regarded as clinically significant point mutations. The clarithromycin-resistant group was treated with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days. Other mutations were regarded as clinically insignificant and were thus treated with the same regimen as the

non-resistance group, which was treated with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 days.

Outcome assessment

^{13}C -urease breath test (^{13}C -UBT; UBiT-IR 300, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan) at least 6–8 weeks after completion of treatment was performed to confirm *H. pylori* eradication. We defined successful eradication of *H. pylori* as a negative ^{13}C -UBT result. All subjects were asked to stop taking PPI at least 2 weeks before ^{13}C -UBT. Compliance was considered low when <90% of the prescribed pills were taken. Patients who did not visit for ^{13}C -UBT after completion of treatment and presented low compliance were excluded from per-protocol (PP) analysis.

Statistical analysis

Continuous variables were calculated as numbers and percentages. *H. pylori* eradication rates were analyzed based on intention-to-treat (ITT) and PP analyses. The eradication rates were compared by the chi-square test. Multivariate logistic regression analysis was performed to evaluate independent risk factors for eradication failure. A 2-sided *P* value less than 0.05 was considered statistically significant. All statistical analyses were carried out using SPSS for Windows, Version 19.0 (IBM Corp., Armonk, New York, USA).

Results

Clinical characteristics of study patients

We recruited 431 consecutive patients who were positive for rapid urease test and examined them for CAMR-related point mutations. Baseline characteristics of patients are described in Table 1. Mean age was 54.7 ± 13.1 (19–89) years and 66.4% of the subjects were male. Among the patients, 329 had peptic ulcer disease and the proportion of the cases of gastric ulcer was similar with that of duodenal ulcer. Moreover, 55 patients had gastric adenoma and 20 patients had gastric adenocarcinoma (Table 1).

Distribution of CAMR-related point mutations

Among the 431 patients enrolled into the study, 50 patients were not detected of any mutations. However, 21.3% of the enrolled patients had clinically significant CAMR-related point mutations. A2143G was the most common point mutation and there were patients who had both A2143G and A2142G mutations. Detailed information regarding the mutations is shown in Table 2. Other detected mutations were regarded as clinically insignificant; among them, T2182C was the most common, and the mutations A2223G, T2190C, and C2195T were detected in six patients (Table 2).

Efficacy of 7-day *H. pylori* eradication regimen tailored to detected CAMR-related point mutations

We assessed the efficacy of 7-day *H. pylori* eradication regimen tailored to detected CAMR-related point mutations in 362 patients. The overall *H. pylori* eradication rate was 83.7%. Based on ITT analysis, the 7-day PAM-treated clarithromycin-resistance group showed a significantly lower eradication rate than the 7-day PAC-treated nonresistance group [55.4% (51/92) vs. 74.3% (252/339), $P = 0.001$] (Figure 2). Based on PP analysis, there was a significant difference between the two groups [66.2% (51/77) vs. 88.4% (252/285), $P = 0.0001$]. (Figure 2). No serious adverse events were reported in both groups.

H. pylori eradication rates according to CAMR-related point mutations

We analyzed *H. pylori* eradication rates according to CAMR-related point mutations and found that there were significant differences. As shown in Table 3, among the clinically significant point mutations, A2142G showed the lowest eradication rate (1/4, 25%). Interestingly, the eradication rate of the PAC treatment group, in which the patients presented no mutations, was 83.3%.

Discussion

To our knowledge, this was the first study to compare the efficacy of *H. pylori* eradication regimens based on the 23S rRNA point mutations related to clarithromycin resistance identified through sequencing. Maastricht recommendations state that susceptibility testing should be performed prior to therapy in regions with high clarithromycin resistance rates¹⁷. A recent meta-analysis demonstrated that susceptibility-guided therapy was superior to empirical therapy¹⁸. Antimicrobial susceptibility-guided therapy as first line therapy may be more logical to avoid misuse of antibiotics in *H. pylori* treatment in the era of increasing antibiotic resistance. However, culture-based methods are time-consuming (10–14 days) and require specific expertise, making their application difficult in clinical practice as first line therapy. There have been several studies about tailored *H. pylori* treatment based on molecular methods^{19–21}. In most studies, only the mutations A2143G and A2142G were detected by DPO-based multiplex PCR. Our study aimed to detect more point mutations other than A2143G and A2142G, as well as investigate the clinical significance of these mutations in treating *H. pylori*.

Among the point mutations identified, 21.3% were clinically significant; among those, A2143G was the most common point mutation (19.5%). The same result was observed in previous studies^{19,21,22}. One patient had the clinically significant A2142C mutation; moreover, T2182C was the most common clinically insignificant mutation as analyzed via sequencing. There have been controversial results regarding whether T2182C is associated with clarithromycin resistance^{10,15}. Of note, the T2182C mutation is the most frequent point mutation associated with clarithromycin resistance in Korea; however, its clinical significance has not been determined^{15,22,23}. A sequencing-based method can detect

more point mutations, including T2182C, than other methods. The factors influencing treatment failure for clinically insignificant CAMR-related point mutations should be clarified in the future.

In the present study, there was a significantly lower eradication rate in the 7-day PAM treatment group of clarithromycin resistance compared with that in the 7-day PAC treatment group of negative clarithromycin resistance [ITT; 55.4% (51/92) vs. 74.3% (252/339), $P = 0.001$, PP; 66.2% (51/77) vs. 88.4% (252/285), $P = 0.0001$]. The lower eradication rate in the mutant type may be explained by the shorter treatment duration and dual resistance to clarithromycin and metronidazole. Similarly, a recent Korean study regarding tailored *H. pylori* eradication regimens based on a DPO-based PCR method found that there was significant differences in the *H. pylori* eradication rates depending on the presence of a 23S rRNA gene point mutation [mutant type vs. wild type; 81.8% (45/55) vs. 94.9% (131/138), $P = 0.004$]. In this study, a 7-day PAM regimen was used to treat clarithromycin-resistant *H. pylori* similar to our study. However, in the recent tailored therapy according to the DPO-based PCR method, 14-day bismuth-based quadruple therapy in the clarithromycin-resistant group showed a higher eradication rate (33/36, 91.7%)²¹.

It has not been fully agreed upon which regimen should be used in patients for primary treatment of clarithromycin-resistant *H. pylori*. Although bismuth-based quadruple therapy showed a higher eradication rate for clarithromycin-resistant *H. pylori*, considering the side effects of administering multiple drugs and the increasing incidence of antibiotic resistance, metronidazole-based triple therapy may be an appropriate alternative therapy. Resistance to metronidazole has increased worldwide; however, in Korea, a decreasing trend in metronidazole resistance was observed in several studies¹⁰. In Korea, the expected rate of dual resistance is lower than 15%; furthermore, metronidazole resistance is known to be partially overcome by increasing the dose and treatment duration¹. Thus, 14 day-PAM treatment may be applied for clarithromycin-resistant *H. pylori* treatment.

In this study, we regarded A-to-G or A-to-C point mutations at positions 2142 and 2143 as clinically significant, while other mutations were regarded as clinically insignificant. Previous studies using the PCR-RFLP system have shown the high frequency of the A2143G or A2144G mutations in clarithromycin-resistant *H. pylori* in both the US and Europe^{16,24}. There was no mutation at position 2144 in our study, indicating that the main 23S rRNA gene mutations inducing clarithromycin resistance are dissimilar in Western and Eastern countries.¹⁴ Moreover, we documented that clinically insignificant point mutations had little influence on the *H. pylori* eradication rate; however, this has yet to be confirmed and fully elucidated.

Considering the increasing incidence of antibiotic resistance, tailored *H. pylori* eradication regimens based on clarithromycin resistance detected via molecular methods for primary treatment may be more cost-effective than empirical treatment²¹. There have been few Korean studies that analyzed the detailed CAMR-related point mutations identified by a sequencing-based method in the era of high clarithromycin resistance. Furthermore, the efficacy of 7-day PAM treatment in primary clarithromycin-resistant *H. pylori* was not determined. To our knowledge, our study is the first relatively large-scale research regarding the

tailored therapy of *H. pylori* based on CAMR-related point mutations identified by sequencing of the 23S rRNA gene.

This study has some limitations. First, we could not perform *H. pylori* culture and antibiotic susceptibility testing.¹⁴ It is reported that there may be discordance between genotype and phenotype²⁵. A future study comparing molecular-based and culture-based methods may be necessary. Second, this was a retrospective study; thus, we could not analyze other factors influencing *H. pylori* eradication rates other than clarithromycin resistance. Interestingly, among the 42 patients who had no point mutations and were treated with a 7-day PAC regimen, only 35 patients were fully eradicated of *H. pylori* infection. This means that there may be complex factors associated with eradication failure, such as cytochrome P450 2C19 (CYP2C19) polymorphism influencing PPI metabolism. Lastly, we could not assess the cost-effectiveness of tailored treatment based on sequencing in comparison with a DPO-based multiplex PCR method.

Conclusion

In conclusion, our study identified multiple point mutations in the 23S rRNA gene as identified by sequencing, and that a 7-day metronidazole-based regimen may be less efficacious in treating clarithromycin-resistant *H. pylori* infection. Therefore, a prospective study comparing different treatment regimens may be needed in optimizing clarithromycin-resistant *H. pylori* treatment.

Abbreviations

Helicobacter pylori (*H. pylori*), ribosomal RNA (rRNA), polymerase chain reaction (PCR), PAC (proton pump inhibitor, amoxicillin, clarithromycin), PAM (proton pump inhibitor, amoxicillin, metronidazole), mucosa-associated lymphoid tissue (MALT),

proton pump inhibitor (PPI), dual priming oligonucleotide (DPO), clarithromycin resistance (CAMR), intention-to treat (ITT), per-protocol (PP), cytochrome P450 2C19 (CYP2C19)

Declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of the study institution, and the protocol conformed with the ethical guidelines of the Declaration of Helsinki. IRB number is 2017–03–005.

Consent for publication

Our study is retrospective study, therefore, we received exemption of consent form from ethics committee of our institution

Availability of data and material

The datasets used and analysed during the current study are available from the corresponding author on reasonable request

Competing interests

The authors declare that they have no competing interests.

Funding

We have no funding sources.

Authors' contributions

SIS participated acquisition of data, statistical analysis, interpretation of data and draft of the manuscript.

BJD and JGK participated acquisition of data

HSK and MKJ provided technical and material support.

HYK provided study supervision.

WGS designed study concept and provided critical revision of the manuscript.

All authors have read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut*. 2017;66(1):6–30.
2. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on *Helicobacter pylori* gastritis. *Gut*. 2015;64(9):1353–1367.

3. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of *Helicobacter pylori* eradication on gastric histology: a systematic review and meta-analysis. *Helicobacter*. 2007;12 Suppl 2:32–38.
4. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after *Helicobacter pylori* eradication: a meta-analysis. *Digestion*. 2011;83(4):253–260.
5. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of *Helicobacter pylori* eradication in preventing gastric cancer. *Ann Gastroenterol*. 2017;30(4):414–423.
6. Lee YC, Chiang TH, Chou CK, et al. Association Between *Helicobacter pylori* Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology*. 2016;150(5):1113–1124.e1115.
7. Choi IJ, Kook MC, Kim YI, et al. *Helicobacter pylori* Therapy for the Prevention of Metachronous Gastric Cancer. *N Engl J Med*. 2018;378(12):1085–1095.
8. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of *Helicobacter pylori* infection in Korea, 2013 revised edition. *J Gastroenterol Hepatol*. 2014;29(7):1371–1386.
9. Shin WG, Lee SW, Baik GH, et al. Eradication Rates of *Helicobacter pylori* in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. *Helicobacter*. 2016;21(4):266–278.
10. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of *Helicobacter pylori* strains and the effect of A2143G point mutation of 23S rRNA on the eradication of *H. pylori* in a single center of Korea. *J Clin Gastroenterol*. 2010;44(8):536–543.
11. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of *Helicobacter pylori* in Korea from 2003 through 2012. *Helicobacter*. 2013;18(3):206–214.
12. Chung WC, Jeon EJ, Oh JH, et al. Dual-priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of *Helicobacter pylori* in bleeding peptic ulcers. *Digestive and Liver Disease*. 2016;48(8):899–903.
13. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. *Helicobacter pylori* and antimicrobial resistance: molecular mechanisms and clinical implications. *Lancet Infect Dis*. 2006;6(11):699–709.
14. Ierardi E, Giorgio F, Iannone A, et al. Noninvasive molecular analysis of *Helicobacter pylori*: Is it time for tailored first-line therapy? *World J Gastroenterol*. 2017;23(14):2453–2458.
15. Kim JM, Kim JS, Kim N, et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in *Helicobacter pylori* strains isolated from Korean patients. *J Microbiol Biotechnol*. 2008;18(9):1584–1589.

- 16.Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S, Munakata A. Clarithromycin-resistance and point mutations in the 23S rRNA gene in *Helicobacter pylori* isolates from Japan. *J Gastroenterol Hepatol*. 2000;15(8):906–909.
- 17.Malfertheiner P. *Helicobacter pylori* Treatment for Gastric Cancer Prevention. *N Engl J Med*. 2018;378(12):1154–1156.
- 18.Lopez-Gongora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for *Helicobacter pylori* infection. *J Antimicrob Chemother*. 2015;70(9):2447–2455.
- 19.Lee HJ, Kim JI, Cheung DY, et al. Eradication of *Helicobacter pylori* according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. *J Infect Dis*. 2013;208(7):1123–1130.
- 20.Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother*. 2013;68(2):450–456.
- 21.Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored *Helicobacter pylori* eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. *J Gastroenterol Hepatol*. 2018.
- 22.Park CG, Kim S, Lee EJ, Jeon HS, Han S. Clinical relevance of point mutations in the 23S rRNA gene in *Helicobacter pylori* eradication: A prospective, observational study. *Medicine (Baltimore)*. 2018;97(33):e11835.
- 23.Kim KS, Kang JO, Eun CS, Han DS, Choi TY. Mutations in the 23S rRNA gene of *Helicobacter pylori* associated with clarithromycin resistance. *J Korean Med Sci*. 2002;17(5):599–603.
- 24.Versalovic J, Osato MS, Spakovsky K, et al. Point mutations in the 23S rRNA gene of *Helicobacter pylori* associated with different levels of clarithromycin resistance. *J Antimicrob Chemother*. 1997;40(2):283–286.
- 25.De Francesco V, Zullo A, Ierardi E, et al. Phenotypic and genotypic *Helicobacter pylori* clarithromycin resistance and therapeutic outcome: benefits and limits. *J Antimicrob Chemother*. 2010;65(2):327–332.

Tables

Table 1. Baseline characteristics of all patients (n=431)

Variables	
Age, mean $\pm$ SD (range)	54.7 $\pm$ 13.1 (15-89)
Male, n (%)	286 (66.4)
Clinical diagnosis, n (%)	
Nodular gastritis	16 (3.7)
Chronic atrophic gastritis	11 (2.6)
Peptic ulcer (GU/DU 164/165)	329 (76.3)
Gastric adenoma	55 (12.8)
Gastric adenocarcinoma	20 (4.6)

GU, gastric ulcer; DU, duodenal ulcer.

Table 2. Distribution of clarithromycin resistance-related point mutations determined through sequencing (n=431)

Point mutation	Number (%)
Clinically significant mutation	92 (21.3)
A2142G	4 (0.9)
A2142C	1 (0.2)
A2143G	84 (19.5)
A2142G + A2143G	3 (0.7)
Clinically insignificant mutation	289 (67.1)
T2182C	283 (65.7)
others	6 (1.4)
No point mutation	50 (11.6)

Table 3. *H. pylori* eradication rates according to clarithromycin resistance-related point mutations (n=362)

Point mutation	Eradication rate (%)
none	35/42 (83.3)
A2142G	1/4 (25)
A2142C	1/1 (100)
A2143G	47/70 (67.1)
A2142G+A2143G	2/2 (100)
T2182C	212/238 (89.1)
Others (A2223G, C2195T)	5/5 (100)

Figures

Figure 1

Flow chart of the study. CAMR, clarithromycin resistance; PAM, proton pump inhibitor, amoxicillin, and metronidazole; PAC, proton pump inhibitor, amoxicillin, and clarithromycin; PP, per-protocol analysis; ITT, intention-to-treat analysis.

Figure 2

Helicobacter pylori eradication rate according to clarithromycin resistance. CAMR, clarithromycin resistance; PAM, proton pump inhibitor, amoxicillin and metronidazole; PAC, proton pump inhibitor, amoxicillin and clarithromycin; PP, per-protocol analysis; ITT, intention-to-treat analysis.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [STROBEChecklist.doc](#)